

# Kathryn Perkins PharmD, MS, RPh

Emerging Leader in Applied Health Economics & Outcomes Research

## CONTACT



+1 360-790-6059



Kathrynperkins28@gmail.com



[linkedin.com/in/kathrynsperkins/](https://www.linkedin.com/in/kathrynsperkins/)

## EDUCATION

### **Doctor of Pharmacy (PharmD) & Graduate Certificate Healthcare Analytics**

University of Southern California  
School of Pharmacy  
May 2024

### **MS, Health Economics & Outcomes Research**

University of Washington  
School of Pharmacy  
June 2025

### **BS, Molecular Biology**

Evergreen State College  
June 2017

## SUMMARY OF EXPERIENCE

- 3 Years of Experience in HEOR (2023-2026)
- 3 Years of experience in clinical pharmacy (2021-2024)
- 9 Years of Experience in the medical field (2017-2026)
- 2 Manuscripts (2 in review)
- 5 Conference Abstract

## TECHNICAL SKILLS

- Cost-Effectiveness Analysis
- Budget Impact Analysis
- Observational Research Design
- Real World Evidence
- Indirect Treatment Comparisons
- PRO Endpoints in Clinical Trials
- Preference Elicitation
- JCA evidence planning
- Global / AMCP Dossier
- Systematic Literature Reviews
- Preference Studies
- Qualitative Study Design
- Digital Health Applications
- Oncology, Biosimilars

## OVERVIEW

Driven strategic HEOR professional with experience designing, executing, and translating studies to meet global and US evidence and access needs. Brings strong technical skills across foundational HEOR methods, real-world evidence, and economic modeling, supported by clinical and hospital systems expertise. Committed to continuous professional growth, fostering positive team culture, and thriving in collaborative, cross-functional environments.

## PROFESSIONAL EXPERIENCE

### **Post-Doctoral Fellow, Global HTA, Value & Evidence, Oncology**

Pfizer | New York, NY | 7/2024 – Present

#### ***Strategic Planning and Execution***

- Co-developed the evidence strategy for 4404 from beginning of phase 3 through launch through identifying evidence gaps, PRO/COA strategy, opportunities for competitive differentiation, Joint Clinical Assessment (JCA) evidence planning, HTA submissions, US payer and pathway submissions, and other market specific evidence needs
- Led and oversaw studies according to integrated evidence plan (IEP) and contributed to IEP updates to support access evidence need
- Initiated and secured cross-functional endorsement for a pathways stakeholder insights study designed to guide US evidence-generation priorities and market access strategy

#### ***Collaboration and Communication***

- Presented study concepts to asset strategy and publication planning committees for approval and to refine strategic scope of future studies
- Collaborated with onseptomab cross-functional team members to refine study scope, build RWE statistical analysis plan (SAP), and prioritize strategic objectives and insights
- Wrote RFPs, conducted proposal reviews and vendor assessments, coordinated vendor communication and file sharing

#### ***Regulatory and Compliance***

- Provided edits to ongoing study protocols and concept elicitation interview guides in response to FDA feedback to support the COA studies essential for regulatory and PFDD guidance adherence
- Supported team in navigating SOPs and staying up to date on study compliance best practices

#### ***Evidence Generation and Analysis***

- Generated real-world evidence on cancer cachexia healthcare resource use and costs across multiple datasets to quantify unmet need and inform strategic planning for value messaging
- Supported indirect treatment comparison studies (Matching adjusted indirect comparison, Multi-level Network meta-regression) to be included in HTA submission
- Built budget impact models to support value messaging and early cost-effectiveness models inform HTA model evidence needs
- Consulted on qualitative study protocols, interview guides, and final reports for concept elicitation studies to inform quantitative clinical outcomes assessments and preference study design
- Supported development and oversight of a multi-stakeholder preference elicitation survey (Best-Worst Scaling)

## KEY SKILLS

### **Business/Administrative Skills**

- RFP Writing and Review
- Proposal Review / Vendor Assessment
- Vendor Management
- Cross-functional alignment & engagement

### **Software Package Skills**

- Data Analysis: R, SAS, SQL, Instant Healthcare Data (IHD)
- AI: Copilot, ChatGPT, Elicit OpenEvidence, Perplexity
- Economic Modeling: Excel, R
- Productivity & Communication: Microsoft Office Suite, Google Workspace, Teams, Slack, Sharepoint, Notion

### **Dataset Experience**

- MarketScan
- Medicare
- NHWS Survey
- Carelon
- Komodo

## MEMBERSHIPS

- Member, International Society for Pharmaco-economics and Outcomes Research (ISPOR)
- Member, Academy of Managed Care Pharmacists (AMCP)

## AWARDS & COMPETITIONS

- 2024 Order of Arête, Distinguished Graduate Student Award, University of Southern California
- 2023 AMCP National P&T Competition, Placed Top 5
- 2022 AMCP Regional P&T Competition, USC School of Pharmacy, 4<sup>th</sup> Place Team

## PROFESSIONAL EXPERIENCE (CONTINUED)

### **Specialized Health Outcomes Intern, HEOR Strategy**

AbbVie / AMCP Foundation | Mettawa, IL | 5/2023 – 8/2023

- Created interactive tool in Excel to explore studies evaluating TNFi cycling vs switching and presented tool to cross-functional teams
- Conducted targeted literature review of TNFi cycling vs switching mechanism of action in rheumatic disease to support value messaging
- Explored claims data study design through acquiring Instant Health Data (IHD) Foundations Certification

### **HEOR and Market Access Extern**

Cencora | Conshohocken, PA | 3/2023 – 5/2023

- Presented on in depth analysis of market barriers to uptake, utilization, and access for digital therapeutics
- Co-authored a white paper on the applications of digital therapeutics and digital health technologies
- Created a client presentation on key trends in managed care

### **Intern Pharmacist**

USC Arcadia Hospital | Arcadia, CA | 7/2021 – 5/2024

- Monitored lab values to inform dosing, reviewed adverse event reports, and counseled patients on medication use
- Developed a new clinical intern program to improve educational opportunities and pharmacy department metrics
- Trained interns and pharmacy technicians on pharmacy workflow, Pyxis fill, unit dosing, and triaging nursing calls

## PUBLICATIONS

- **Perkins K**, Roth J, Carlson, J. Measuring the Impact of Cachexia on Resource Utilization and Costs in Patients with Pancreatic, Lung, and Colorectal Cancers in the United States: An Insurance Claims Database Analysis. (Submission Pending JMCP)
- Roth JA, Kratochvil D, **Perkins K**, Zhang W. Cost-Efficiency Modeling of Conversion to Biosimilar Rituximab-Based R-CHOP in Diffuse Large B-Cell Lymphoma in Medicare. Manuscript for submitted to the Journal of Medical Economics. 2025.(Under Review)
- Cristobal E, **Perkins K**, Kang C, Chen S. Impact of a Mock OSCE on Student Confidence in Applying the Pharmacists' Patient Care Process. Pharmacy (Basel). 2024;12(2):54.
- Shen G, Moua KTY, **Perkins K**, et al. Precision sirolimus dosing in children: The potential for model-informed dosing and novel drug monitoring. Front Pharmacol. 2023;14:1126981.

## CONFERENCE ABSTRACTS

- **Perkins K**, Roth J, Carlson, J. Impact of Cachexia on Resource Utilization and Costs in Pancreatic, Lung, and Colorectal Cancers in the United States: A Claims Database Analysis. ISPOR 2026.
- **Perkins K**, Roth J, Carlson J. Cost-Effectiveness of Olanzapine Compared to Standard of Care for Cancer Cachexia Management: A Markov Model. Poster presented at the Western PharmacoEconomics Conference (WPEC). Seattle, WA. March 2025.
- **Perkins K**, Roth J, Carlson J. Real-World Evidence of Biosimilars in Oncology. Poster presented at the University of Washington, School of Pharmacy, Corporate Advisory Board Meeting. Seattle, WA. Sept 2024.
- **Perkins K**, Zueger P. A review of TNFi cycling vs MOA switching outcomes after first line TNFi in rheumatic conditions. Presented at AMCP Nexus Conference, Orlando, FL. Oct 2023.